How does parecoxib sodium affect systemic prostacyclin formation and platelet thromboxane?

Parecoxib sodium, a prodrug of the selective COX-2 inhibitor valdecoxib, reduces systemic (and therefore possibly endothelial) prostacyclin formation without affecting platelet thromboxane; the clinical relevance of these observations has not been established.